2025 cureshank impact report

As we close out 2025, we are proud to reflect on a year marked by unprecedented scientific progress and bold steps forward in our mission: accelerating the development of effective therapies for Phelan-McDermid syndrome (PMS). Our strategy has focused on removing barriers, building foundational tools, and enabling industry-grade research — all designed to ensure that the PMS therapeutic pipeline expands, accelerates, and ultimately delivers safe, effective treatments to our community.

Click the image to read the full report.